Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD): Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)

Key figures

What the numbers say

In 2024, Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) rose 4.03 percentage points on 2023 (from 16.02% to 20.05%).

Across the 23 yearly changes before that (2001 to 2023), the average change was +0.7 percentage points and a typical year strayed about 3.79 percentage points from that (the standard deviation). This year's change was 0.9 standard deviations above that average, so it was an ordinary year: it sits within the range of normal year-to-year movement.

On record, the biggest yearly rise was 8.32 percentage points in 2021 and the biggest yearly fall was 12.11 percentage points in 2020. The numbers show how large and when, not why; for the cause, look at what happened in that country in those years.

From 2015 to 2024 there is no clear straight-line trend: a straight line explains less than 1% of the movement over 10 observed years, so the value is moving around more than it is heading anywhere.

Worked out from the yearly values above. How the checks work: standard deviation, z-scores and straight-line trends.

How it compares

See how every economy compares in the full ranking.

What this measures

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).

Regional and income-group figures are computed by the World Bank as a weighted average.

All 25 values

Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in nearby economies

• Afghanistan — 14% (2024)
• Algeria — 74% (2019)
• Djibouti — 38% (2024)
• Egypt, Arab Rep. — 27% (2024)
• Libya — 70% (2023)
• Morocco — 72% (2024)
• Pakistan — 14% (2024)
• Tunisia — 32% (2024)

More health data for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)

• Population ages 00-04, female (% of female population) — 10.88% (2025)
• Population ages 00-04, male (% of male population) — 11.14% (2025)
• Population ages 0-14, female — 119.33 million (2025)
• Population ages 0-14, female (% of female population) — 32.26% (2025)
• Population ages 0-14, male — 125 million (2025)
• Population ages 0-14, male (% of male population) — 33.02% (2025)
• Population ages 0-14, total

Reading data like this

• Where to find free public data, and how to check it before you trust it — 2 min read
• Data analysis examples: 6 worked from one dataset — 3 min read
• Real change or random noise? A plain guide to reading your numbers — 2 min read

Questions people ask

What is Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)?

20.05% in 2024, according to the World Bank (World Development Indicators).

How has it changed since 2000?

It is up 20.05 percentage points from 0% in 2000. The highest value was 24.59% in 2019 and the lowest 0% in 2000.

Is the latest change in antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) unusual for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?

Source

World Bank, World Development Indicators, indicator SH.HIV.PMTC.ZS, licensed CC BY 4.0. Original source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), uri: https://aidsinfo.unaids.org/, publisher: UNAIDS, date accessed: 2025-08-27, date published: 2025-07 Figures are fetched from the World Bank API and refreshed monthly; see the series on data.worldbank.org. The full definition and method are in the World Bank's metadata glossary. Comparisons use the same World Bank release.

Want to ask your own questions of data like this? Try AnalyzeIt: upload a file or ask about public data in plain words, and every figure comes with its working.